 ST. GALLEN, Switzerland SAN DIEGO, Calif.--BUSINESS WIRE--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. NASDAQ: TVTX today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal phase-III clinical studies for the treatment of 